A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

  • Kaplan, Zane (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date20/09/21 → 19/09/26

Keywords

  • treatment safety
  • treatment efficacy
  • Thrombocytopenia
  • phase 3 study
  • multicentre trial

Clinical Trial Phase

  • Phase III (a & b)